Mural Oncology plc
Mural Oncology plc (MURA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MURA · as of Sep 30, 2025
Ownership Breakdown
62
Institutional Holders
▼ 5 vs Q2
$11.01M
Total Inst. Value
▼ $9.32M vs Q2
17.34M
Shares Outstanding
freeFloat 69.99%
5.32M
13F Shares Held
▼ 2.91M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MURA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 736.2K | 4.26% | 4.26% | $1.52B | Nov 14, 2025 | ▲ 700.4K |
ORBIMED ADVISORS LLC pharmaceutical preparations | 588.8K | 3.41% | 3.41% | $1.22B | Nov 14, 2025 | — held |
NEWTYN MANAGEMENT, LLC pharmaceutical preparations | 522.9K | 3.03% | 3.03% | $1.08B | Nov 14, 2025 | ▼ 47.1K |
OMERS ADMINISTRATION CORP pharmaceutical preparations | 511.0K | 2.96% | 2.96% | $1.06B | Nov 14, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 454.7K | 2.63% | 2.63% | $941.25M | Nov 7, 2025 | ▼ 318.1K |
RANGELEY CAPITAL, LLC pharmaceutical preparations | 305.0K | 1.77% | 1.77% | $631.35M | Nov 14, 2025 | ▲ 258.5K |
BLACKROCK, INC. pharmaceutical preparations | 287.6K | 1.67% | 1.67% | $595.29M | Nov 12, 2025 | ▲ 1.2K |
RBF CAPITAL, LLC pharmaceutical preparations | 283.9K | 1.64% | 1.64% | $587.70M | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 258.5K | 1.50% | 1.50% | $535.07M | Nov 14, 2025 | ▼ 57.6K |
CITADEL ADVISORS LLC pharmaceutical preparations | 258.3K | 1.50% | 1.50% | $534.58M | Nov 14, 2025 | ▲ 185.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
16
Increased
+1.62M shares11
New Positions
first time holders15
Decreased
−961.8K shares0
Sold Out
fully exitedNet shares change (top 50)
+661.7K
+1.62M / −961.8K
Net new holders
+12
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MURA insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
29
Sell transactions
0.00
Buy/Sell ratio
$2M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Hickey Benjamin director | Dec 5, 2025 | D-Return | 15,021 | $3.61 | $54.2K | 0 | Form 4 ↗ |
Hickey Benjamin director | Dec 5, 2025 | D-Return | 8,637 | $2.56 | $22.1K | 0 | Form 4 ↗ |
Hickey Benjamin director | Dec 5, 2025 | D-Return | 8,462 | $3.35 | $28.3K | 0 | Form 4 ↗ |
Loew Caroline Chief Executive Officer | Dec 5, 2025 | D-Return | 293,059 | $2.04 | $596.4K | 0 | Form 4 ↗ |
Loew Caroline Chief Executive Officer | Dec 5, 2025 | D-Return | 379,690 | $5.48 | $2.08M | 0 | Form 4 ↗ |
Loew Caroline Chief Executive Officer | Dec 5, 2025 | D-Return | 134,225 | $3.43 | $460.4K | 0 | Form 4 ↗ |
Loew Caroline Chief Executive Officer | Dec 5, 2025 | D-Return | 90,025 | $5.39 | $485.2K | 0 | Form 4 ↗ |
Cuss Francis M director | Dec 5, 2025 | D-Return | 8,637 | $2.56 | $22.1K | 0 | Form 4 ↗ |
Cuss Francis M director | Dec 5, 2025 | D-Return | 8,462 | $3.35 | $28.3K | 0 | Form 4 ↗ |
Cuss Francis M director | Dec 5, 2025 | D-Return | 15,021 | $3.61 | $54.2K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Mural Oncology plc (MURA) is primarily owned by institutional investors, who hold approximately 30.7% of total shares outstanding. Company insiders own approximately 30.01%, while retail and public investors account for the remaining 39.31%.
The largest institutional shareholder of Mural Oncology plc is SUSQUEHANNA INTERNATIONAL GROUP, LLP, holding approximately 736,200 shares — equal to 4.26% of outstanding shares — as of September 30, 2025.
A total of 62 institutional investors currently hold MURA stock, with a combined institutional value of approximately $11,014,553 as of the most recent 13F filing period.
Frequently asked questions
MURA ownershipMural Oncology plc (MURA) is primarily owned by institutional investors, who hold approximately 30.7% of shares. The largest shareholder is SUSQUEHANNA INTERNATIONAL GROUP, LLP with a 4.26% stake. Company insiders hold 30.01%. Data sourced from SEC Form 13F as of September 30, 2025.